vutrisiran vutrisiran vutrisiran, sold under the brand name amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hattr) amyloidosis in adults. it is a small interfering rna (sirna) that interferes with the expression of the transthyretin (ttr) gene. vutrisiranclinical datatrade namesamvuttraother namesaln-65492license data us dailymed: vutrisiran routes ofadministrationsubcutaneousatc coden07xx18 (who) legal statuslegal status us: ℞-only eu: rx-only identifierscas number1867157-35-4drugbankdb16699as salt: dbsalt003187uniigb4i2ji8uias salt: 28o0wp6z1pkeggd11917as salt: d11916 vutrisiran was approved for medical use in the united states in june 2022, and in the european union in september 2022. history the u.s. food and drug administration (fda) granted the application for vutrisiran orphan drug designation. society and culture legal status on 21 july 2022, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product amvuttra, intended for treatment of hereditary transthyretin-mediated (hattr) amyloidosis. amvuttra was designated as an orphan medicinal product on 25 may 2018. the applicant for this medicinal product is alnylam netherlands b.v. vutrisiran was approved for medical use in the european union in september 2022. names vutrisiran is the international nonproprietary name (inn).